InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR... Show more
IFRX moved below its 50-day moving average on January 08, 2026 date and that indicates a change from an upward trend to a downward trend. In of 52 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .
The 50-day moving average for IFRX moved below the 200-day moving average on January 14, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IFRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
IFRX broke above its upper Bollinger Band on December 24, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Momentum Indicator moved above the 0 level on January 14, 2026. You may want to consider a long position or call options on IFRX as a result. In of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for IFRX just turned positive on January 14, 2026. Looking at past instances where IFRX's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IFRX advanced for three days, in of 222 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 93 cases where IFRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IFRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.372) is normal, around the industry mean (27.929). P/E Ratio (0.000) is within average values for comparable stocks, (51.397). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.899). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (909.091) is also within normal values, averaging (329.547).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IFRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
a developer of biopharmaceutical products
Industry Biotechnology
A.I.dvisor tells us that IFRX and NNVC have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IFRX and NNVC's prices will move in lockstep.
| Ticker / NAME | Correlation To IFRX | 1D Price Change % | ||
|---|---|---|---|---|
| IFRX | 100% | +7.00% | ||
| NNVC - IFRX | 30% Poorly correlated | -4.17% | ||
| COGT - IFRX | 29% Poorly correlated | +7.11% | ||
| TVTX - IFRX | 28% Poorly correlated | -0.62% | ||
| VERA - IFRX | 28% Poorly correlated | -1.41% | ||
| BOLD - IFRX | 28% Poorly correlated | +1.61% | ||
More | ||||